Analysis of protective efficacy against heterologous and heterosubtypic influenza virus challenge by mucosal rAd/NP vaccination.

<p>BALB/c mice were immunized intranasally or sublingually with 1×10⁷ PFU or 1×10⁸ PFU of rAd/NP. Control mice were immunized intranasally with rAd/Mock. Mice that received rAd/NP via sublingual route were boosted two weeks after the primary vaccination. Subsequently mice in all vaccination groups were challenged with 10 LD₅₀ of CA04 (H1N1) virus, A/Philippines (H3N2) virus, or A/Vietnam (H5N1) virus. (A) Body weight and (B) survival rate were recorded daily. Error bars in weight loss graph indicated mean ± SEM of five mice per group.